文献速递肝胆胰外科围术期管理与 ERAS

转移性肾上腺皮质癌的外科治疗:多脏器联合切除是否有价值?

Surgical management of metastatic adrenocortical carcinoma: Is there a role for multivisceral resection?
PubMed 文献 · Surgery · 2025-09-26

该回顾性研究分析了1998至2024年间153例转移性肾上腺皮质癌患者,按治疗方式分为多脏器联合切除、单纯肾上腺切除和未手术三组。多脏器联合切除组中位总生存33个月,单纯肾上腺切除22个月,未手术7个月;多因素分析显示两种手术方式均与更长生存独立相关,但复杂手术需在有经验的多学科团队中审慎选择患者。

要点

  • 多脏器联合切除与单纯肾上腺切除均与转移性肾上腺皮质癌更长总生存独立相关。
  • 多脏器联合切除中位总生存33个月,未手术仅7个月,但需注意选择偏倚。
  • 复杂手术应限于有经验的多学科团队审慎选择的患者。

核心结论

  • 与未手术管理相比,包括多脏器联合切除在内的减瘤手术可能与转移性肾上腺皮质癌总生存改善相关。
  • 鉴于复杂手术的潜在风险,应在有经验的多学科团队中审慎选择患者实施。

研究设计与样本

  • 单中心回顾性分析1998至2024年153例转移性肾上腺皮质癌患者。
  • 按治疗方式分为多脏器联合切除组(24%)、单纯肾上腺切除组(18%)和未手术管理组(58%)。
  • 采用Kaplan-Meier分析和Cox比例风险模型评估总生存。

主要发现

  • 153例患者中52%为女性,中位年龄49岁(四分位距36-59岁),68%肿瘤有功能。
  • 最常见转移部位为肺(71%)和肝(66%),整块切除最常见为根治性肾切除(64%)和部分肝切除(47%)。
  • 中位总生存:多脏器联合切除33个月,单纯肾上腺切除22个月,未手术管理7个月(P < .0001)。
  • 多因素分析显示多脏器联合切除(HR=0.31,95%CI 0.18-0.50,P < .0001)和单纯肾上腺切除(HR=0.50,95%CI 0.28-0.88,P = .017)与更长总生存独立相关。

临床怎么用

  • 对转移性肾上腺皮质癌患者,可考虑在经验丰富的多学科团队评估后实施减瘤手术,包括多脏器联合切除。
  • 手术决策需权衡复杂操作的潜在风险,审慎选择合适患者。

局限性

  • 回顾性单中心设计,可能存在选择偏倚。
  • 手术组与未手术组之间基线特征可能不均衡,影响因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent data suggest that cytoreductive surgery in metastatic adrenocortical carcinoma) may improve survival. However, successful removal of locally invasive primary tumors in such patients may require complex en bloc and/or multivisceral resection, for which the survival benefits remain unclear. METHODS: We retrospectively analyzed 153 patients with metastatic adrenocortical carcinoma treated at our institution from 1998 to 2024. Patients were categorized into 3 groups based on treatment approach: multivisceral resection, adrenalectomy alone, and nonoperative management. Kaplan-Meier analysis and Cox proportional hazards models were used to evaluate overall survival across these groups. RESULTS: Among 153 patients (52% female; median age 49 years, interquartile range: 36-59 years), 24% underwent multivisceral resection, 18% had adrenalectomy alone, and 58% were managed nonoperatively. Overall, 68% of tumors were functional. The most frequent metastatic sites were the lung (71%) and liver (66%). The most frequent en bloc procedures included radical nephrectomy (64%) and partial hepatectomy (47%). The median overall survival was 33 months after multivisceral resection, 22 months after adrenalectomy alone, and 7 months with nonoperative management (P < .0001). On multivariable analysis, multivisceral resection (hazards ratio = 0.31, 95% confidence interval: 0.18-0.50, P < .0001) and adrenalectomy alone (hazards ratio = 0.50, 95% confidence interval: 0.28-0.88, P = .017) were independently associated with longer overall survival compared with nonoperative management. CONCLUSION: Cytoreductive surgery, including multivisceral resection, may be associated with improved survival in metastatic adrenocortical carcinoma compared with nonoperative management. However, given the potential risks of these complex operations, they should be judiciously performed in select patients by experienced multidisciplinary teams.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Shariq OA, Kensing B, Landry JP, et al. Surgical management of metastatic adrenocortical carcinoma: Is there a role for multivisceral resection? Surgery. 2025. PMID: 41006153. doi:10.1016/j.surg.2025.109696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。